{
    "asthma": {
      "market_size_usd_bn": 18.2,
      "cagr_percent": 6.4,
      "top_competitors": ["GSK", "AstraZeneca", "Novartis"],
      "india_patient_burden_mn": 34,
      "insight": "High patient burden with moderate competition suggests opportunity for differentiated adjunct therapies."
    },
    "alzheimer": {
      "market_size_usd_bn": 9.5,
      "cagr_percent": 11.2,
      "top_competitors": ["Biogen", "Eisai"],
      "india_patient_burden_mn": 4.5,
      "insight": "High growth but limited approved therapies; strong repurposing potential."
    }
  }
  